Difference between revisions of "Vancomycin-resistant enterococcus"

 
(One intermediate revision by one other user not shown)
Line 5: Line 5:
 
==Antimicrobial Options<ref>Arias CA et al. Management of multidrug-resistant enterococcal infections. Clin Microbiol Infect. 2010 Jun; 16(6): 10.1111/j.1469-0691.</ref><ref>Rivera AM and Boucher HW. Current Concepts in Antimicrobial Therapy Against Select Gram-Positive Organisms: Methicillin-Resistant Staphylococcus aureus, Penicillin-Resistant Pneumococci, and Vancomycin-Resistant Enterococci. Mayo Clin Proc. 2011 Dec; 86(12): 1230–1243.</ref>==
 
==Antimicrobial Options<ref>Arias CA et al. Management of multidrug-resistant enterococcal infections. Clin Microbiol Infect. 2010 Jun; 16(6): 10.1111/j.1469-0691.</ref><ref>Rivera AM and Boucher HW. Current Concepts in Antimicrobial Therapy Against Select Gram-Positive Organisms: Methicillin-Resistant Staphylococcus aureus, Penicillin-Resistant Pneumococci, and Vancomycin-Resistant Enterococci. Mayo Clin Proc. 2011 Dec; 86(12): 1230–1243.</ref>==
 
*[[Gentamicin]] 1 mg/kg q8hrs IV
 
*[[Gentamicin]] 1 mg/kg q8hrs IV
**Use [[streptomycin]] for gentamicin resistance
+
**Use [[streptomycin]] for [[gentamicin]] resistance
 
**Add [[ampicillin]] 12 g q24hrs IV if treating [[endocarditis]] or [[vancomycin]] if suspicious for MRSA
 
**Add [[ampicillin]] 12 g q24hrs IV if treating [[endocarditis]] or [[vancomycin]] if suspicious for MRSA
 
*[[Linezolid]] 600 mg PO/IV q12hrs, with exception of bacteremia since agent is bacteriostatic
 
*[[Linezolid]] 600 mg PO/IV q12hrs, with exception of bacteremia since agent is bacteriostatic
Line 15: Line 15:
 
*[http://www.antimicrobe.org/Enterococcus%20table%202.pdf VRE antimicrobial table from www.antimicrobe.org]
 
*[http://www.antimicrobe.org/Enterococcus%20table%202.pdf VRE antimicrobial table from www.antimicrobe.org]
  
==Sources==
+
==References==
 +
<references/>
  
<references/>
+
[[Category:ID]]
[[Category:Pharmacology]][[Category:ID]]
 

Latest revision as of 17:32, 31 August 2017

Background

Antimicrobial Options[1][2]

See Also

References

  1. Arias CA et al. Management of multidrug-resistant enterococcal infections. Clin Microbiol Infect. 2010 Jun; 16(6): 10.1111/j.1469-0691.
  2. Rivera AM and Boucher HW. Current Concepts in Antimicrobial Therapy Against Select Gram-Positive Organisms: Methicillin-Resistant Staphylococcus aureus, Penicillin-Resistant Pneumococci, and Vancomycin-Resistant Enterococci. Mayo Clin Proc. 2011 Dec; 86(12): 1230–1243.